EUCTR2008-001003-38-GB进行中（未招募）不适用
A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascular risk.
The Royal Group of Hospitals, Belfast Trust0 个研究点开始时间: 2008年6月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- BMI >27kg/m2
- •- Age >18 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Significant cardiac, renal or hepatic disease
- •- History of depression or anxiety
- •- Women of childbearing potential unless on appropriate contraception
- •- Pregnant women
- •- Already using pharmacotherapy to induce weight loss
研究者
相似试验
已完成
不适用
A study investigating rimonabant and diet in overweight subjectsObesityISRCTN00253207Belfast Health and Social Care Trust (UK)24
终止
3 期
High Density Lipoprotein TurnoverObesityNCT00408148Sanofi64
终止
3 期
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic DrugDiabetes Mellitus Type 2ObesityNCT00478595Sanofi458
终止
3 期
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and ExerciseDiabetes Mellitus Type 2ObesityNCT00478972Sanofi321
终止
3 期
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 DiabetesFatty LiverNCT00577148Sanofi89